Richard Whitley to Time Factors
This is a "connection" page, showing publications Richard Whitley has written about Time Factors.
Connection Strength
0.379
-
Treatment of herpes simplex virus infections in pediatric patients: current status and future needs. Clin Pharmacol Ther. 2010 Nov; 88(5):720-4.
Score: 0.051
-
Review of recent HSV recurrent-infection treatment studies. Herpes. 2007 Jun; 14(1):23-6.
Score: 0.040
-
Phase specific analysis of herpes zoster associated pain data: a new statistical approach. Stat Med. 2001 Aug 30; 20(16):2429-39.
Score: 0.027
-
Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001 Feb; 20(2):127-33.
Score: 0.026
-
Herpes zoster: risk categories for persistent pain. J Infect Dis. 1999 Jan; 179(1):9-15.
Score: 0.022
-
The identification of risk factors associated with persistent pain following herpes zoster. J Infect Dis. 1998 Nov; 178 Suppl 1:S71-5.
Score: 0.022
-
Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis. 1997 May; 175(5):1080-6.
Score: 0.020
-
Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis. 1996 Feb; 22(2):341-7.
Score: 0.018
-
Use of clinical and neuroimaging characteristics to distinguish temporal lobe herpes simplex encephalitis from its mimics. Clin Infect Dis. 2015 May 01; 60(9):1377-83.
Score: 0.017
-
Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet. 2015 May 02; 385(9979):1729-1737.
Score: 0.017
-
A genome-wide comparative evolutionary analysis of herpes simplex virus type 1 and varicella zoster virus. PLoS One. 2011; 6(7):e22527.
Score: 0.013
-
Protection against herpetic ocular disease by immunotherapy with monoclonal antibodies to herpes simplex virus glycoproteins. Intervirology. 1988; 29(1):39-49.
Score: 0.010
-
Studies on herpes simplex virus type 1 glycoproteins using monoclonal antibodies. Virology. 1986 Jun; 151(2):385-9.
Score: 0.009
-
Regulatory challenges: lessons from recent West Nile virus trials in the United States. Contemp Clin Trials. 2006 Jun; 27(3):254-9.
Score: 0.009
-
Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. Cancer Gene Ther. 2005 Apr; 12(4):359-68.
Score: 0.009
-
Interim summary of mortality in herpes simplex encephalitis and neonatal herpes simplex virus infections: vidarabine versus acyclovir. J Antimicrob Chemother. 1983 Sep; 12 Suppl B:105-12.
Score: 0.008
-
Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr. 2003 Jul; 143(1):16-25.
Score: 0.008
-
Management of infections. Pediatr Ann. 1983 Jun; 12(6):445-9.
Score: 0.008
-
Early vidarabine therapy to control the complications of herpes zoster in immunosuppressed patients. N Engl J Med. 1982 Oct 14; 307(16):971-5.
Score: 0.007
-
Mucocutaneous herpes simplex virus infections in immunocompromised patients. A model for evaluation of topical antiviral agents. Am J Med. 1982 Jul 20; 73(1A):236-40.
Score: 0.007
-
Plasma levels and urinary excretion of vidarabine after repeated dosing. Clin Pharmacol Ther. 1980 May; 27(5):690-6.
Score: 0.006
-
Application of competitive PCR to cerebrospinal fluid samples from patients with herpes simplex encephalitis. J Clin Microbiol. 1998 Aug; 36(8):2229-34.
Score: 0.005
-
A rapid protein A binding radioimmunoassay for the evaluation of antiviral agents. J Virol Methods. 1994 Jul; 48(2-3):273-9.
Score: 0.004
-
A controlled trial of acyclovir for chickenpox in normal children. N Engl J Med. 1991 Nov 28; 325(22):1539-44.
Score: 0.003
-
Rapid detection of herpes-simplex-virus DNA in cerebrospinal fluid of patients with herpes simplex encephalitis. Lancet. 1990 Feb 24; 335(8687):440-1.
Score: 0.003
-
Infant pneumonitis associated with cytomegalovirus, Chlamydia, Pneumocystis, and Ureaplasma: follow-up. Pediatrics. 1987 Jan; 79(1):76-83.
Score: 0.002
-
Effect of primary and recurrent cytomegalovirus infections upon graft and patient survival after renal transplantation. Transplantation. 1979 Dec; 28(6):443-6.
Score: 0.001
-
Serum antibody levels as risk factors in the dissemination of herpes zoster. Arch Intern Med. 1979 Dec; 139(12):1341-5.
Score: 0.001
-
Identification of patients with increased risk of infection with herpes simplex virus after renal transplantation. J Infect Dis. 1979 Oct; 140(4):487-92.
Score: 0.001